Neurofibromatosis

18 registered clinical trials studyying Neurofibromatosis — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 NCT07102394	Johns Hopkins University	Phase 1
Recruiting	Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsia NCT07088991	AstraZeneca	—
Terminated	A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I NCT04461886	Nobelpharma	Phase 3
Recruiting	GROWing Up With Rare GENEtic Syndromes NCT04463316	dr. Laura C. G. de Graaff-Herder	—
Completed	Relationship Between Psychosocial Factors, Health Literacy, Quality of Life and Satisfaction With Medical Visi NCT02435628	Massachusetts General Hospital	—
Completed	Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Typ NCT02211768	National Cancer Institute (NCI)	Phase 1
Completed	Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults NCT02101736	University of Alabama at Birmingham	Phase 2
Completed	Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype NCT02298270	Massachusetts General Hospital	N/A
Completed	Validating Pain Scales in Children and Young Adults NCT01639950	National Cancer Institute (NCI)	—
Completed	Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain NCT01633008	National Cancer Institute (NCI)	EARLY_Phase 1
Terminated	Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas NCT01402817	Indiana University	Phase 2
Completed	Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexifo NCT01140360	Kent Robertson	Phase 1 / Phase 2
Completed	Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas NCT01275586	Indiana University	EARLY_Phase 1
Recruiting	Natural History Study of Patients With Neurofibromatosis Type 2 NCT00598351	National Institute of Neurological Disorders and Stroke (NINDS)	—
Completed	Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma NCT00589784	Memorial Sloan Kettering Cancer Center	Phase 2
Completed	Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Ple NCT01673009	Indiana University	Phase 2
Completed	Quality of Friendships in Children With Neurofibromatosis NCT00508235	M.D. Anderson Cancer Center	—
Completed	Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1 NCT00754780	Mayo Clinic	Phase 2